In disease models such as metabolic syndrome, nonalcoholic fatty liver disease, and obesity, β-Klotho activation has shown the potential to improve fatty acid oxidation, reduce inflammation levels, regulate liver cholesterol synthesis, improve islet β-cell function, and reduce islet fibrosis. This evidence concerns the gene KLB and obesity due to melanocortin 4 receptor deficiency.